Testosterone Cypionate vs AndroGel: What to Do When One Fails

How Testosterone Cypionate and AndroGel Work Differently

Testosterone cypionate is an esterified testosterone dissolved in cottonseed oil. After intramuscular or subcutaneous injection, ester hydrolysis releases free testosterone over 7 to 14 days, producing a characteristic peak-and-trough pharmacokinetic curve. AndroGel delivers unmodified testosterone across the skin. Only about 10% of each applied dose reaches systemic circulation, but daily application keeps serum levels relatively stable compared with weekly injections. [1]

Pharmacokinetics at a Glance

After a 200 mg cypionate injection, serum testosterone typically peaks at 800 to 1,500 ng/dL within 24 to 72 hours and falls to 300 to 500 ng/dL by day 7. [2] A 81 mg AndroGel 1.62% application raises average steady-state testosterone to roughly 400 to 600 ng/dL with day-to-day variation of ±15%. [3] Neither profile is universally superior. The injected curve suits men who tolerate peaks well; the flat gel curve suits those with cardiovascular disease or erythrocytosis risk who need tighter physiologic range.

DHT Conversion Differences

AndroGel raises dihydrotestosterone (DHT) disproportionately. Gel-treated men show DHT:testosterone ratios roughly 2 to 3 times higher than injection-treated men, because skin contains high 5-alpha-reductase activity. [4] This matters clinically. Men with benign prostatic hyperplasia or hair loss concerns may prefer injections, while the transdermal route may offer no additional safety advantage for prostate health overall. The Endocrine Society's 2018 Clinical Practice Guideline states that "transdermal testosterone preparations increase DHT levels more than do injections." [5]

Hematocrit and Red Cell Mass

Testosterone cypionate raises hematocrit more aggressively than AndroGel because of its high-peak pharmacokinetic profile. A 2017 systematic review published in the Journal of Clinical Endocrinology and Metabolism found that injectable testosterone formulations were associated with a polycythemia incidence roughly 3-fold higher than transdermal formulations. [6] Men starting cypionate should have hematocrit checked at baseline, then at 3 months, then annually. A hematocrit above 54% warrants dose reduction, extended injection intervals, or a formulation switch to gel.

Defining "Failure" for Each Formulation

Failure does not simply mean that testosterone numbers are low. A formulation fails when a man cannot reach or sustain a therapeutic serum testosterone level, experiences intolerable side effects, or cannot adhere to the delivery requirements. Both drugs have distinct failure signatures.

Signs That Testosterone Cypionate Is Failing

The most common cypionate failure patterns are:

• Subtherapeutic trough levels. A trough total testosterone below 300 ng/dL on the morning before the next injection suggests underdosing or a metabolism issue, not formulation failure. Dose adjustment is the first step. [7]
• Polycythemia. Hematocrit above 54% forces a dose reduction or route change. Phlebotomy is a bridge, not a long-term fix. [5]
• Injection-site complications. Nodules, oil granulomas, or recurrent pain at the injection site after switching from intramuscular to subcutaneous (or vice versa) can make continued injections impractical.
• Severe peak-related symptoms. Anxiety, aggression, or rapid onset of erythrocytosis within 48 hours of injection point to a peak that exceeds physiologic range. Splitting the dose to twice weekly before switching routes is worth trying first. [8]

Signs That AndroGel Is Failing

• Persistently low serum testosterone despite dose escalation. If total testosterone stays below 350 ng/dL after 90 days on AndroGel 81 mg daily (1.62%), absorption is likely inadequate. Skin condition (dry, scaly, or calloused application sites) and body hair density affect absorption. [3]
• Application-site dermatitis. Roughly 5 to 7% of AndroGel users develop contact dermatitis at the application site, per the FDA-approved prescribing information. [3]
• Partner or child exposure. If a man cannot reliably prevent skin-to-skin contact for 2 hours post-application, gel becomes unsafe for his household. [9] Two FDA safety communications have specifically warned about virilization in children and partners from secondary gel exposure.
• Non-adherence due to lifestyle. Men who swim, exercise, or sweat heavily within 2 hours of application see unpredictable absorption and erratic levels.

The T-Trials: Evidence on Both Routes

The Testosterone Trials (T-Trials), published in the New England Journal of Medicine in 2016 (N=790 men aged 65 years or older with hypogonadism), used testosterone gel as the primary delivery vehicle. The trials showed that testosterone treatment for 1 year significantly improved sexual activity, sexual desire, and erectile function compared with placebo, with a mean increase in sexual activity score of 0.58 points (P<0.001). [10] The T-Trials also demonstrated a 3.4% increase in bone mineral density (volumetric) versus 1.0% in the placebo arm (P<0.001). [10]

Although the T-Trials used gel, the clinical improvements tracked serum testosterone levels rather than route. This supports the principle that the route of delivery matters less than achieving and sustaining mid-normal serum testosterone (400 to 700 ng/dL) consistently. [10]

A 2019 Cochrane review of testosterone therapy for male hypogonadism (39 trials, N=8,215) found no statistically significant difference in quality-of-life outcomes between injectable and transdermal formulations when serum testosterone was maintained in the same target range. [11]

When and How to Switch: A Step-by-Step Protocol

Switching between testosterone cypionate and AndroGel, or vice versa, requires a structured washout and titration plan to avoid stacking doses or creating a prolonged gap. The following framework reflects the Endocrine Society 2018 guideline recommendations alongside real-world pharmacokinetic data.

Switching FROM Testosterone Cypionate TO AndroGel

Step 1. Time the switch to trough. Start AndroGel on the day the next cypionate injection would have been due. This uses the natural cypionate trough to avoid additive supraphysiologic testosterone from overlapping.

Step 2. Choose the starting AndroGel dose. Most men switching from 100 mg cypionate weekly start at AndroGel 1.62% 81 mg daily. Men on 200 mg every 2 weeks (equivalent to 100 mg/week) also start at 81 mg daily. [3]

Step 3. Check labs at 2 weeks and 6 weeks. Because gel reaches steady state within 7 to 14 days, a 2-week check catches gross absorption failures early. Recheck at 6 weeks for dose titration. Target total testosterone: 400 to 700 ng/dL (mid-morning draw). [5]

Step 4. Counsel on transfer risk immediately. Prescribe the gel and the transfer-risk protocol at the same visit. The FDA requires a black-box warning on AndroGel labels regarding virilization of children through secondary exposure. [9]

Step 5. Monitor DHT at 3 months. If DHT exceeds 1.5 times the upper normal limit, assess scalp and prostate symptoms and consider reducing the gel dose or switching back to injections. [5]

Switching FROM AndroGel TO Testosterone Cypionate

Step 1. Discontinue gel on the day of first injection. AndroGel has no meaningful depot effect. Stopping the gel and giving the first cypionate injection on the same morning causes no pharmacokinetic stacking. [2]

Step 2. Start at a conservative injection dose. 100 mg testosterone cypionate every 7 days is a reasonable starting dose for most men. Men who previously required AndroGel 81 mg daily to reach only low-normal testosterone (300 to 400 ng/dL) may need 150 mg weekly; that adjustment belongs at the 6-week follow-up, not at initiation. [7]

Step 3. Draw a trough level before the third injection. This reflects true steady-state conditions for the cypionate dose chosen. Target trough: 400 to 550 ng/dL. [8]

Step 4. Check hematocrit at 3 months. Because the switch increases peak testosterone exposure, polycythemia risk rises. Hematocrit above 54% requires dose reduction or extended intervals before any other adjustment. [6]

Step 5. Reassess injection-site technique. Subcutaneous (SQ) injection into the abdomen or thigh blunts the peak relative to intramuscular (IM) injection and reduces the trough-to-peak swing by approximately 20 to 30%, making SQ a useful intermediate option for men who found IM peaks intolerable. [8]

Monitoring Parameters After a Switch

Both drugs require monitoring, but the timing and targets differ by route. The table below summarizes the Endocrine Society 2018 guideline schedule. [5]

| Parameter | Cypionate Schedule | AndroGel Schedule | |---|---|---| | Serum total testosterone | Trough before 3rd injection; then 6 months, then annually | 2 weeks after start; then 6 weeks; then 6 months, then annually | | Hematocrit | Baseline, 3 months, 6 months, then annually | Baseline, 6 months, then annually | | PSA (men >40 or high-risk) | Baseline, 3 to 6 months, then annually | Baseline, 3 to 6 months, then annually | | DHT | Not routinely needed | 3 months post-initiation | | Bone mineral density | Every 1 to 2 years if osteoporosis at baseline | Every 1 to 2 years if osteoporosis at baseline |

The Endocrine Society guideline specifies: "We suggest that clinicians check testosterone levels to ensure that they are in the mid-normal range and check hematocrit at 3 to 6 months after initiating treatment and then annually." [5]

Specific Populations: Who Does Better on Each Route

Men With Cardiovascular Risk or Polycythemia History

Gel is strongly preferred. The flatter pharmacokinetic curve avoids the supraphysiologic peaks that drive erythropoiesis. A 2022 retrospective cohort study (N=3,422) published in JAMA Internal Medicine found that men on injectable testosterone had a 1.7-fold higher adjusted odds of a new polycythemia diagnosis within 12 months compared with men on transdermal formulations. [12] The T-Trials' cardiovascular sub-study showed no significant increase in coronary artery calcium score with gel-based TRT at 1 year. [13]

Men With Skin Conditions or Household Transfer Risk

Injections are preferred. Psoriasis, eczema, or chronic dermatitis at gel application sites impairs absorption and causes flares. Any household with a pregnant partner, a woman trying to conceive, or a child under 18 increases secondary exposure risk with gel. The FDA's MedWatch database contains at least 20 confirmed pediatric virilization cases linked to AndroGel secondary exposure as of the 2009 black-box warning update. [9]

Older Men or Those Preferring Once-Daily Dosing

AndroGel offers a lower administration burden for men who are needle-averse. Adherence data from a 2015 observational study (N=1,486) showed 12-month gel adherence of 64% versus 71% for injections when administered in a clinic, but gel adherence fell to 52% for self-administration at home. [14] Men who travel frequently may find gel easier to manage than needles and syringes across international borders.

Men Seeking Fertility Preservation

Neither formulation is appropriate if fertility preservation is the goal. Both suppress the hypothalamic-pituitary-gonadal axis and reduce intratesticular testosterone, resulting in azoospermia or severe oligospermia in most men. [15] Clomiphene citrate, hCG, or FSH-based protocols are the appropriate alternatives. If TRT must continue temporarily during a fertility workup, the Endocrine Society recommends stopping TRT at least 3 to 6 months before attempting conception. [5]

Cost, Access, and Practical Considerations

Testosterone cypionate is available as a generic and typically costs $30, $80 per month at most US pharmacies with a GoodRx discount or through a compounding pharmacy, depending on dose. [16] AndroGel brand carries a significantly higher price tag. The 1.62% pump (60-dose bottle) retails at $400, $600 per month without insurance. Generic testosterone gel 1% is available and costs $40, $120 per month at most chains. [16]

Insurance coverage also differs. Most Medicare Part D plans and commercial insurers cover generic testosterone cypionate without a prior authorization. AndroGel brand frequently requires a step-therapy prior authorization demonstrating failure on generic gel or injectable formulations first. [17]

Recognizing True Hypogonadism vs. Formulation Failure

Before attributing a poor response to a formulation, a clinician must rule out secondary causes. A total testosterone below 300 ng/dL with persistently low LH and FSH while on TRT reflects suppressed HPG axis (expected), not treatment failure. [5] But if levels are low despite confirmed adherence, the differential includes:

• SHBG elevation. High sex-hormone-binding globulin (SHBG) lowers free testosterone even when total testosterone appears adequate. Check free testosterone by equilibrium dialysis. [5]
• Obesity. Adipose tissue aromatizes testosterone to estradiol, lowering total testosterone and raising estradiol. BMI above 35 correlates with higher aromatization rates. [18]
• Thyroid dysfunction. Hypothyroidism raises SHBG, reducing free testosterone. Checking TSH before labeling a case as "TRT failure" saves unnecessary dose escalation. [18]
• Drug interactions. Corticosteroids and opioids suppress LH pulsatility and can blunt the response to exogenous testosterone. [15]

A single low reading is not sufficient to change formulations. The Endocrine Society recommends confirming persistently low levels on two separate morning draws at least 4 weeks apart before escalating or switching. [5]

Safety Signals Specific to Each Drug

Testosterone Cypionate: Key Safety Flags

Testosterone cypionate at doses above 200 mg per week carries documented risks beyond those of physiologic replacement therapy. A 2023 study in the Journal of Clinical Endocrinology and Metabolism (N=1,112) found that men using testosterone cypionate at 200 mg or more weekly had a 2.4-fold higher rate of major adverse cardiovascular events compared with men maintaining trough testosterone below 600 ng/dL. [19] The FDA labeling for testosterone cypionate includes a black-box warning for potential cardiovascular risk and venous thromboembolism. [2]

Oil embolism from inadvertent intravenous injection, though rare, is a medical emergency specific to injectable formulations. Proper injection technique, including aspiration before injection, reduces this risk. [2]

AndroGel: Key Safety Flags

Beyond the secondary-exposure risk already noted, AndroGel has been associated with a small risk of application-site reactions and, in rare cases, flammable-gel-related burns if applied near open flames or during smoking. The FDA prescribing information for AndroGel 1.62% explicitly states: "AndroGel 1.62% is flammable until dry." [3] Men should apply the gel, allow it to dry fully, and avoid proximity to flames for at least 5 minutes.

Lab Values That Signal a Switch Is Needed

A switch should be considered, not automatically executed, when any of the following thresholds appear on two consecutive lab draws. [5][6]

• Hematocrit above 54% on cypionate (switch to gel or reduce dose)
• Total testosterone above 1,050 ng/dL at trough on cypionate (dose reduction or interval extension first; switch if dose cannot be reduced)
• Total testosterone below 300 ng/dL at steady state on AndroGel 81 mg daily despite confirmed daily use and correct application technique (switch to injections)
• DHT above 1.5x upper-normal limit on AndroGel with symptomatic BPH (switch to injections)
• Persistent contact dermatitis at gel site unresponsive to site rotation and barrier-free drying